Opko健康 OPK 深 沪
等待开盘 05-19 09:30:00 美东时间
1.135
+0.035
+3.18%
华盛通- 最 高1.145
- 今 开1.09
- 成交量 211.37万股
- 最 低 1.09
- 昨 收 1.10
- 总市值 8.57亿
- 52周最高 1.60
- 市盈率 静 --
- 换手率 0.28%
- 52周最低 0.9769
- 委 比 29.82%
- 总股本 7.55亿
- 历史最高 19.20
- 量 比 1.07
- 振 幅 5.00%
- 历史最低 0.8516
- 每 手 1
- 风险率 0.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
Entera Bio Ltd. reported Q1 2026 financial results and business updates, highlighting progress in its oral peptide therapeutics pipeline. Key developments include the submission of a streamlined Phase 3 protocol for EB613, an oral anabolic tablet for postmenopausal osteoporosis, and expanded collaboration with OPKO for EB612, an oral long-acting PTH tablet for hypoparathyroidism. Additionally, data for EB618, an oral dual GLP-1/glucagon tablet fo...
05-08 20:05
Opko Health shares are trading lower after the company reported worse-than-expected Q1 sales results and issued Q2 sales guidance below estimates.
Opko Health shares are trading lower after the company reported worse-than-expe...
04-30 00:52
Barrington Research Downgrades OPKO Health to Market Perform
Barrington Research analyst Michael Petusky downgrades OPKO Health (NASDAQ:OPK) from Outperform to Market Perform.
04-29 20:57
OPKO Health Q1 2026 Earnings Call: Complete Transcript
OPKO Health (NASDAQ:OPK) reported first-quarter financial results on Tuesday. T...
04-29 16:34
OPKO Health Sees Q2 Sales $127.000M-$132.000M vs $136.329M Est
OPKO Health (NASDAQ:OPK) sees Q2 sales of $127.000 million-$132.000 million vs $136.329 million analyst estimate.
04-29 04:08
Earnings Scheduled For April 28, 2026
Companies Reporting Before The Bell • LGI Homes (NASDAQ:LGIH) is likely to repo...
04-28 19:11
OPKO Health's ModeX Therapeutics Says First Participants Dosed In Phase 1 Clinical Trial Evaluating MDX2301 For Prevention Of COVID-19
ModeX Therapeutics Inc., an OPKO Health company (NASDAQ:OPK), today announced that the first participants have been dosed in a Phase 1 clinical trial evaluating MDX2301 for the prevention of COVID-19. MDX2301 is a
04-08 20:05
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates
Entera Bio Ltd., a leader in oral peptide development, reported financial and business updates for 2025, highlighting progress in its pipeline, including EB613 for osteoporosis, EB612 for hypoparathyroidism, and EB618 for metabolic syndromes. FDA alignment on BMD as a primary endpoint for EB613 was achieved, with Phase 3 plans advancing. The company also expanded collaborations with OPKO Health and reported cash reserves of $14.9 million, despite...
03-27 20:05
Opko Health Adds Independent Director to Strengthen Governance
Opko Health ( ($OPK) ) has provided an update. On March 18, 2026, OPKO Health a...
03-20 05:19
